All In Biotech

Drug Trial Radar · NCT06678542

Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects

A Phase 1, Open-label, Single-site, Randomized, Single-dose, Two-Period, Crossover Study to Assess the Relative Bioavailability of GP681 Powder for Oral Suspension and Tablet Formulations in Healthy Chinese Male Subjects

Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Sep 27, 2024

Primary completion

Feb 16, 2025

Study completion Feb 16, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the relative bioavailability and pharmacokinetic profile of a single oral dose of the test formulation, GP681 Powder for Oral Suspension (20 mg/sachet), compared to the reference formulation, GP681 tablet (20 mg/tablet), in healthy Chinese male subjects. The secondary objectives are to assess the safety of a single oral dose of the GP681 Powder for Oral Suspension (20 mg/sachet) and GP681 tablet (20 mg/tablet) in healthy Chinese male subjects, as well as the palatability (taste acceptability) of the GP681 Powder for Oral Suspension.

Conditions

  • Healthy Participants

Interventions

  • GP681 tabletDrug

    GP681 tablet, 20 mg, single oral dose in each Group.

  • GP681 Powder for Oral SuspensionDrug

    GP681 Powder for Oral Suspension, 20 mg, single oral dose in each Group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax)Time frame: Up to 360 hours post-dose
  2. Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration[AUC(0-T)]Time frame: Up to 360 hours post-dose
  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time[AUC(INF)]Time frame: Up to 360 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Women and Children's hospital of Ningbo University

    Ningbo, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.